Expected Moves

Key interim pipeline data update evaluating clinical efficacy, modeling a breakout to $1.80 on success or a sharp haircut to $0.45 on mixed results.

Critical capital raise to extend the corporate runway, presenting a severe dilution risk toward $2.10 or a non-dilutive partnership target of $2.10.

Year-end financial results and fiscal 2027 outlook, determining whether shares can recover to $1.40 or break lower to $0.60 on liquidity exhaustion.